Gsk Plc · LSE:GSK
Gsk — GlaxoSmithKline — Deutsche Bank Securities Healthcare Conference (May 2004)
15 slides from Gsk's conference presentation, May 2004
Slide 1: Deutsche Bank Securities Healthcare Conference
Deutsche Bank Securities Healthcare Conference David Stout President, Pharmaceutical Operations GlaxoSmithKline
Slide 2: Q1 Results
Q1 Results • On track to deliver guidance • Strong underlying pharma business – Offset Paxil losses • Good Consumer healthcare performance
Slide 3: Financial Summary
Financial Summary* 1Q04 1Q03 % change £m £m CER £ Sales 4,943 5,222 2 (5) - Pharma Sales 4,180 4,466 1 (6) Trading profit 1,562 1,796 (2) (13) Other operating income/(expense) 35 (20) Net interest/(expense) (43) (35) Profit before tax 1,576 1,763 1 (11) Tax rate 27.5% 27.0% Earnings 1,119 1,263 0 (1
Slide 4: Pharmaceuticals Performance
Pharmaceuticals Performance £m Global US Pharma Sales 4,180 2,093 1% 1% Paxil IR Sales* 190 48 (51%) (77%) Pharma Sales 3,990 2,045 ex-Paxil IR 6% 10% *Excludes Paxil CR sales. % Growth is CER
Slide 5: Key growth drivers of GSK's current portfolio
Key growth drivers of GSK’s current portfolio Respiratory Seretide £581m +22% Diabetes Avandia £238m +18% CNS Lamictal £153m +29% Anti-Viral Valtrex £133m +31% CV Coreg £94m +27% Reported Q104 Global Sales and CER growth
Slide 6: Driving Advair growth
Driving Advair growth “U R” ND GE N ER OU TR “Y EA TE D” “OLDER” - COPD
Slide 7: TDI Score (Improvement in Dyspnea)
Advair is 2x more effective than Combivent in reducing breathlessness in COPD [1] 3.0 Advair * 2.5 * TDI Score (Improvement in Dyspnea) 2.0 * 1.5 1.0 Combivent 0.5 0.0 Weeks 0 2 4 6 8 [1] Donohue J., et. al. Chest 2003;124:128S *p<0.001 ADVAIR vs Combivent and clinically meaningful difference (ie.,
Slide 8: New indication set to drive share in Paediatricians
New indication set to drive share in Paediatricians >4yrs Advair share of controller market within specialty Approved 22/4/04 27% Primary Care 15% Paediatrician 0% 5% 10% 15% 20% 25% 30% Source: Verispan SPA. Share of Asthma/COPD Controller Market within Specialty (February 2004)
Slide 9: Recent large study shows majority of asthma patients are uncontrolled
Recent large study shows majority of asthma patients are uncontrolled Assessment of 59,538 patients (Typical GP patient population) 73% 24% Controlled Uncontrolled Source: Tricore Market Research May 2002-Dec 2003. 1561 (3%) patients were classified undetermined. Uncontrolled defined as asthma sympt
Slide 10: Avandia/Avandamet
12% Avandia/Avandamet • Q104: £238m +18% NRx OAD Weekly Market Share 11% • GSK’s No. 2 franchise with big Avandamet opportunities to come: launched – ’04 Avandaryl launch 10% Generic metformin ER – ’05 psoriasis filing launched – ’06 outcome studies report 9% Actos 8% September-02 December-02 March-
Slide 11: Key Product Growth Drivers 1Q04
Key Product Growth Drivers 1Q04 £153m +29% – Growth driven by bi polar indication – Growth in NRx +67% (March 04) £133m +31% – Only product with a claim to reduce transmission – Once Daily treatment driving growth £94m +27% – Growth in NRx + 48% (March 04) – Significant mortality benefit vs. Metopro
Slide 12: GSK sales force strength
GSK sales force strength Source: Verispan US Sales Force Structures and Strategies 2003 Physician Ranking Tables
Slide 13: Pipeline - Outlook for 2004
Pipeline - Outlook for 2004 Advair Pediatric Epivir/Ziagen Avandaryl Vesicare Fraxiparine* Arixtra* Launches *Conditional on completion of Sanofi-Aventis merger
Slide 14: Pipeline - Outlook for 2004
Pipeline - Outlook for 2004 Boniva Advair alvimopan Pediatric Epivir/Ziagen Requip (RLS) 406381 Avandaryl Nelarabine dual Cox-2 inhib. 685698 Vesicare Boostrix allergic rhinitis 363162 Fraxiparine* Priorix Tetra (EU) depression 572016 Arixtra* Rotarix (Lat Am) dual kinase inhib. Launches Filings Lat
Slide 15: Slide 15
GlaxoSmithKline — Deutsche Bank Securities Healthcare Conference (May 2004) on 6ix